New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a rare, but severe form of cancer, with an incidence that varies significantly within and among different countries around the world. It develops in about one to two persons per million of the general population, leading to thousands of deaths every year world...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fonc.2018.00091/full |
id |
doaj-daaf84faf23b4b3299b66abd38a54d73 |
---|---|
record_format |
Article |
spelling |
doaj-daaf84faf23b4b3299b66abd38a54d732020-11-25T01:29:37ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2018-04-01810.3389/fonc.2018.00091338839New Perspectives on Diagnosis and Therapy of Malignant Pleural MesotheliomaMarika Rossini0Paola Rizzo1Ilaria Bononi2Anthony Clementz3Roberto Ferrari4Roberto Ferrari5Fernanda Martini6Mauro G. Tognon7Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, School of Medicine, University of Ferrara, Ferrara, ItalyDepartment of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, School of Medicine, University of Ferrara, Ferrara, ItalyDepartment of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, School of Medicine, University of Ferrara, Ferrara, ItalyDepartment of Natural Sciences and Geography, Concordia University Chicago, River Forest, IL, United StatesDepartment of Medical Sciences, Section of Internal Medicine and Cardiorespiratory, School of Medicine, University of Ferrara, Ferrara, ItalyE.S. Health Science Foundation, GVM Care & Research, Maria Cecilia Hospital, Cotignola, ItalyDepartment of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, School of Medicine, University of Ferrara, Ferrara, ItalyDepartment of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, School of Medicine, University of Ferrara, Ferrara, ItalyMalignant pleural mesothelioma (MPM) is a rare, but severe form of cancer, with an incidence that varies significantly within and among different countries around the world. It develops in about one to two persons per million of the general population, leading to thousands of deaths every year worldwide. To date, the MPM is mostly associated with occupational asbestos exposure. Asbestos represents the predominant etiological factor, with approximately 70% of cases of MPM with well-documented occupational exposure to asbestos, with the exposure time, on average greater than 40 years. Environmental exposure to asbestos is increasingly becoming recognized as a cause of mesothelioma, together with gene mutations. The possible roles of other cofactors, such as viral infection and radiation exposure, are still debated. MPM is a fatal tumor. This cancer arises during its early phase without clinical signs. Consequently, its diagnosis occurs at advanced stages. Standard clinical therapeutic approaches include surgery, chemo- and radiotherapies. Preclinical and clinical researches are making great strides in the field of this deadly disease, identifying new biomarkers and innovative therapeutic approaches. Among the newly identified markers and potential therapeutic targets, circulating microRNAs and the Notch pathway represent promising avenues that could result in the early detection of the tumor and novel therapeutic approaches.http://journal.frontiersin.org/article/10.3389/fonc.2018.00091/fullmalignant pleural mesotheliomaasbestosgenebiomarkermicroRNAsimian virus 40 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Marika Rossini Paola Rizzo Ilaria Bononi Anthony Clementz Roberto Ferrari Roberto Ferrari Fernanda Martini Mauro G. Tognon |
spellingShingle |
Marika Rossini Paola Rizzo Ilaria Bononi Anthony Clementz Roberto Ferrari Roberto Ferrari Fernanda Martini Mauro G. Tognon New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma Frontiers in Oncology malignant pleural mesothelioma asbestos gene biomarker microRNA simian virus 40 |
author_facet |
Marika Rossini Paola Rizzo Ilaria Bononi Anthony Clementz Roberto Ferrari Roberto Ferrari Fernanda Martini Mauro G. Tognon |
author_sort |
Marika Rossini |
title |
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma |
title_short |
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma |
title_full |
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma |
title_fullStr |
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma |
title_full_unstemmed |
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma |
title_sort |
new perspectives on diagnosis and therapy of malignant pleural mesothelioma |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2018-04-01 |
description |
Malignant pleural mesothelioma (MPM) is a rare, but severe form of cancer, with an incidence that varies significantly within and among different countries around the world. It develops in about one to two persons per million of the general population, leading to thousands of deaths every year worldwide. To date, the MPM is mostly associated with occupational asbestos exposure. Asbestos represents the predominant etiological factor, with approximately 70% of cases of MPM with well-documented occupational exposure to asbestos, with the exposure time, on average greater than 40 years. Environmental exposure to asbestos is increasingly becoming recognized as a cause of mesothelioma, together with gene mutations. The possible roles of other cofactors, such as viral infection and radiation exposure, are still debated. MPM is a fatal tumor. This cancer arises during its early phase without clinical signs. Consequently, its diagnosis occurs at advanced stages. Standard clinical therapeutic approaches include surgery, chemo- and radiotherapies. Preclinical and clinical researches are making great strides in the field of this deadly disease, identifying new biomarkers and innovative therapeutic approaches. Among the newly identified markers and potential therapeutic targets, circulating microRNAs and the Notch pathway represent promising avenues that could result in the early detection of the tumor and novel therapeutic approaches. |
topic |
malignant pleural mesothelioma asbestos gene biomarker microRNA simian virus 40 |
url |
http://journal.frontiersin.org/article/10.3389/fonc.2018.00091/full |
work_keys_str_mv |
AT marikarossini newperspectivesondiagnosisandtherapyofmalignantpleuralmesothelioma AT paolarizzo newperspectivesondiagnosisandtherapyofmalignantpleuralmesothelioma AT ilariabononi newperspectivesondiagnosisandtherapyofmalignantpleuralmesothelioma AT anthonyclementz newperspectivesondiagnosisandtherapyofmalignantpleuralmesothelioma AT robertoferrari newperspectivesondiagnosisandtherapyofmalignantpleuralmesothelioma AT robertoferrari newperspectivesondiagnosisandtherapyofmalignantpleuralmesothelioma AT fernandamartini newperspectivesondiagnosisandtherapyofmalignantpleuralmesothelioma AT maurogtognon newperspectivesondiagnosisandtherapyofmalignantpleuralmesothelioma |
_version_ |
1725095971852910592 |